$57.2 Million is the total value of venBio Partners L.P.'s 3 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was 25.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Sell | Apellis Pharmaceuticals, Inc | $31,828,000 | -56.1% | 1,790,102 | -45.7% | 55.67% | -25.6% | |
| MNLO | Menlo Therapeutics Inc. | $14,396,000 | +21.3% | 1,461,552 | 0.0% | 25.18% | +105.6% | |
| VRNA | Verona Pharma PLCsponsored ads | $10,946,000 | -8.4% | 875,000 | 0.0% | 19.15% | +55.2% | |
| Exit | Nabriva Therapeutics PLC | $0 | – | -177,957 | -100.0% | -0.64% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Apellis Pharmaceuticals, Inc | 5 | Q4 2018 | 77.1% |
| Verona Pharma PLC | 5 | Q4 2018 | 22.2% |
| Menlo Therapeutics Inc. | 4 | Q4 2018 | 33.9% |
| Nabriva Therapeutics PLC | 3 | Q2 2018 | 12.6% |
View venBio Partners L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2019-02-14 |
| 13F-HR | 2018-11-14 |
| 13F-HR | 2018-08-14 |
| 13F-HR | 2018-04-25 |
| 13F-HR | 2018-04-25 |
View venBio Partners L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.